Back to Journals » Therapeutics and Clinical Risk Management » Volume 2 » Issue 1

Transdermal buprenorphine in the management of persistent pain – safety aspects

Authors Rudolf Likar

Published 15 March 2006 Volume 2006:2(1) Pages 115—125

Rudolf Likar

Pain Clinic, General Hospital Klagenfurt, Klagenfurt, Austria

Abstract: By virtue of their efficacy, opioid analgesics have long been used for the treatment of both acute and chronic pain. Concerns regarding their safety and tolerability have frequently prevented this class of drugs achieving their full therapeutic potential, and their reported association with drug abuse and dependence has led to a reduced acceptance by many patients. Indeed, there is a variety of opioid-like side effects which are common to all members of the class, but some opioids have a more favourable safety profile than others. Buprenorphine is a semisynthestic opioid with a µ-agonistic and κ-antagonistic receptor-binding profile. Studies over the past two decades have shown buprenorphine to have a complex and unique pharmacological profile, which results in enhanced therapeutic benefits combined with a favourable safety profile. Having been underused before, the development of a new transdermal drug delivery system for buprenorphine has revived interest in this substance. Transdermal buprenorphine (Gruenenthal GmbH, Aachen, Germany) provides a noninvasive method of rate-controlled drug release ensuring constant and predictable serum buprenorphine levels over a prolonged period. This preparation has been shown to be advantageous for long-term treatment of chronic pain patients providing reliable pain control, few adverse events, and good patient acceptance.

 

Keywords: opioids, chronic pain, buprenorphine, transdermal buprenorphine, safety

Download Article [PDF] 

Readers of this article also read:

Real-world effectiveness of amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide in high-risk patients and other subgroups

Assaad-Khalil SH, Najem R, Sison J, Kitchlew AR, Cho BL, Ueng KC, DiTommaso S, Shete A

Vascular Health and Risk Management 2015, 11:71-78

Published Date: 21 January 2015

Engineering practice variation through provider agreement: a cluster-randomized feasibility trial

McCarren M, Twedt EL, Mansuri FM, Nelson PR, Peek BT

Therapeutics and Clinical Risk Management 2014, 10:905-912

Published Date: 28 October 2014

Multiple cardiovascular comorbidities and acute myocardial infarction: temporal trends (1990–2007) and impact on death rates at 30 days and 1 year

McManus DD, Nguyen HL, Saczynski JS, Tisminetzky M, Bourell P, Goldberg RJ

Clinical Epidemiology 2012, 4:115-123

Published Date: 7 May 2012

Critical appraisal of pralatrexate in the management of difficult-to-treat peripheral T cell lymphoma

Casanova M, Medina-Pérez A, Moreno-Beltran M, Mata-Vazquez M, Rueda A

Therapeutics and Clinical Risk Management 2011, 7:401-408

Published Date: 7 October 2011

Profile of ciclesonide for the maintenance treatment of asthma

Singas E, Karpel JP

Therapeutics and Clinical Risk Management 2011, 7:351-358

Published Date: 19 August 2011